Yes, AE37 was studied in a Phase II study and its
Post# of 36537
(Total Views: 357)
Posted On: 09/28/2020 4:27:21 PM
Yes, AE37 was studied in a Phase II study and its efficacy was still measured positively ten years out:
“In the AE37 arm of this trial, we found patients with advanced stage, HER2 under-expression, and TNBC may benefit from AE37 vaccination, and those with both advanced stage and HER2 under-expression have a significant clinical benefit to AE37 vaccination. Specifically, demonstrating earlier DFS plateau that was maintained for up to the ten years of follow-up.” (DFS is disease free survival.)
https://link.springer.com/article/10.1007/s10549-020-05638-x
“In the AE37 arm of this trial, we found patients with advanced stage, HER2 under-expression, and TNBC may benefit from AE37 vaccination, and those with both advanced stage and HER2 under-expression have a significant clinical benefit to AE37 vaccination. Specifically, demonstrating earlier DFS plateau that was maintained for up to the ten years of follow-up.” (DFS is disease free survival.)
https://link.springer.com/article/10.1007/s10549-020-05638-x
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼